INTRODUCTION
============

The etiologic role of human papillomavirus (HPV) in cervical cancer was well recognized. Even though more than 200 types of HPV have been identified in humans \[[@B1]\], only thirteen have been classified as carcinogenic by the International Agency for Research on Cancer (IARC) \[[@B2]\]. HPV belongs to the Papillomaviridae family with 16 genera. Most of the carcinogenic types belong to either alpha 7 genus (HPV18, 39, 45, and 59) or alpha 9 genus (HPV16, 31, 33, 35, 52, and 58). The remaining oncogenic types were grouped under alpha 5 (HPV51) or 6 (HPV56 and HPV66). IARC has classified HPV 68 as probably carcinogenic with HPV26, 53, 67, 70, 73, and 82 were grouped as possibly carcinogenic. The causal association of HPV in uterine cervical carcinogenesis was well established and this oncogenic virus was stated to be a biomarker for overall recurrence and central pelvic recurrence which is more frequent in the initial 2 years after chemoradiation. The detection of high-risk HPV DNA after the definite therapy may point towards the risk of recurrence and variable survival outcome. The possibility of relapse of cervical cancer is high during the initial 2 years of completed treatment. As per the International Federation of Gynecology and Obstetrics staging, surgery is mainly reserved for early-stage diseases Ia, Ib1, and stage IIa. Meanwhile, stage IIb, IIIa, IIIb, IVa, and IVb are managed by chemoradiation. Clinical trials have revealed that concurrent Cisplatin-based chemoradiation is the standard regimen for treatment of stages Ib2, IIb--IVa \[[@B3][@B4]\]. However, almost one-fourth of the treated cases experience central pelvic recurrence after chemoradiation \[[@B5]\].

During follow-up Pap smear test also known as Pap test is often performed, after radical hysterectomy as well as chemoradiation to perceive the early dysplastic changes in the vaginal vault or cervix. However, the Pap test is not recommended during the first year after radiotherapy as well as hysterectomy owing to the alteration of cells and tissues \[[@B6]\]. Previous studies have reported a greater likelihood of relapse in cervical cancer cases with persistent high-risk HPV infection \[[@B7][@B8]\]. The integration of the viral genome into the host genome is an important event in the progression of a normal cell to the intraepithelial lesion and invasive cancer. The 2 molecular methods of HPV DNA testing are hybrid capture assay and polymerase chain reaction (PCR). The hybrid capture is a signal amplification assay that uses a combination of antibody capture and chemiluminescent signal detection. The system uses RNA probes that reacts with 13 high-risk HPV DNAs and 5 low risk HPV DNAs. The RNA: DNA hybrids are detected with multiple antibodies conjugated to alkaline phosphatase. The results are interpreted by reading the signal from chemiluminescent reaction. In PCR assays, DNA will be extracted from the clinical samples which will be amplified by 1-step PCR or nested PCR using general or type-specific primers targeting the L1 capsid region. PCR has been used for HPV detection, genotyping, and viral load determination. A broad spectrum of HPV types can be screened by means of primer-mediated PCR assays. Following amplification using primers, individual HPV genotypes are identified using a variety of methods. By means of real-time quantitative PCR, viral load (concentration) data can be generated from reaction curves generated. The Detection of HPV DNA by PCR testing may play an important role in the early recognition of recurrence, especially after pelvic irradiation \[[@B9][@B10]\].

There is a sparsity of data regarding the prognostic role of HPV DNA testing in cervical cancer follow-up from low-income countries which bear 85% global cervical cancer burden \[[@B11]\] and available results are conflicting. In the present literature review, we tried to analyze, whether HPV testing in the post-radiotherapy setting will be helpful in detecting the early recurrence in cervical cancer cases.

In India, cervical cancer incidence rates are often underestimated and 5-year age-standardized relative survival rate of cervical cancer is much lower than that of many South East Asian countries \[[@B12]\]. This is mainly attributed to delayed diagnosis, inadequate treatment and absence of regular follow-up. Molecular detection of HPV may facilitate early diagnosis of residual and early recurrent cancers after radiotherapy \[[@B13]\]. During the initial years, molecular testing is more sensitive than cytology because of radiation induced distinct morphologic changes. We observed a limited number of quantitative analysis regarding this topic.

MATERIALS AND METHODS
=====================

The systematic review was carried out as per the standard systematic review guidelines prescribed by major agencies namely Cochrane Collaboration (<https://www.cochrane.org>) and Campbell Collaboration (<https://www.campbellcollaboration.org>). We further modified the meta-analysis component suited for the synthesis of sensitivity and specificity results.

1. Description of the condition {#sec1}
-------------------------------

HPV DNA positivity: HPV DNA positivity is indicative of intermittent viral shedding from latent infection, reinfection, a newly acquired infection, autoinoculation from epithelial sites (oral cavity and anogenital areas), or transient detection of viral DNA from a recent sexual act \[[@B14]\].

HPV DNA negativity: HPV DNA negativity implies host specific virologic control or latency rather than viral clearance or eradication \[[@B14]\].

Recurrence (relapse) of cervical cancer: If the regrowth of the local tumour or distant metastasis occurs after 6 months of definitive treatment, the cancer is considered recurrent \[[@B15]\].

Residual disease is the one which develops within 6 months of primary treatment \[[@B16]\]. Majority of the recurrences happen within the first 2 years of treatment and 90% relapses occur within 5 years \[[@B17]\].

2. Study protocol {#sec2}
-----------------

A comprehensive electronic literature search was performed to assess all the published literature in English between 1984 and 2018 regarding the persistence of HPV in cervical cancer cases after radiotherapy. The electronic databases included were PubMed/Medline, Scopus, and Google Scholar. Relevant articles in English were retrieved combining search terms of "human papillomavirus OR HPV AND cervical cancer AND radiotherapy NOT head and neck cancer." A manual library search for articles published in the peer-reviewed journals was performed. The search builders were checked for their reproducibility before the final search. The references cited in the retrieved articles were also analyzed to increase the search sensitivity. The search was last updated on September 30th, 2018.

The accuracy of the test was assessed by sensitivity, specificity, positive likelihood ratio, negative likelihood ratio, and odds ratio (OR) including 95% confidence interval (CI).

3. Inclusion process and criteria: {#sec3}
----------------------------------

Cohort studies in which histologically confirmed cervical cancer cases treated by radiotherapy, screened by HPV molecular assays and followed up for at least 1-year post-radiation were included. Studies with no molecular testing for HPV, no data on relapses/recurrences, no histological correlation with outcome, carried out in immunocompromised individuals and not followed up for 1 year were excluded.

4. Data extraction {#sec4}
------------------

The pre-designed and pre-tested proforma was employed to extract the data. The proforma focused on the year of publication, study setting, country, pre/post radiation status, HPV DNA testing, follow-up and relapse rate. From the full-text articles, data were extracted by one reviewer which was reviewed by a second reviewer. The disagreements were discussed with a third reviewer, who was an expert and consensus was drawn. We carried out a 3-stage selection process for the final inclusion of the studies in the systematic review. In the first stage, one reviewer assessed each title from 758 titles (records) for the appropriateness for inclusion in the review. If found inappropriate, the articles were rejected (n=388) and all the other articles were moved to the second stage of selection. In the second stage, abstract of 370 titles were obtained and 2 reviewers independently scrutinized all such abstracts. All the non-relevant and duplicate studies were rejected (n=341) and the remaining 29 studies were moved to the third stage. In the third stage, full-text articles of 29 studies were obtained and were reviewed by [@B2] authors independently. The studies chosen by both the reviewers were included and in the case of disagreement between reviewers, a third reviewer adjudged the selection process. Studies with no molecular testing for HPV, no data on relapses/recurrences, no histological correlation with outcome and not followed up for a minimum period of 1 year were excluded. Ten prospective cohort studies were included in the quantitative synthesis (meta-analysis). The study selection process is shown in the PRISMA chart ([Fig. 1](#F1){ref-type="fig"}).

![PRISMA chart detailing the study selection process. The flow diagram demonstrating the number of studies identified, records screened, full-text articles evaluated for the eligibility, and the studies included in the systematic review and meta-analysis.](jgo-31-e20-g001){#F1}

5. Quality assessment {#sec5}
---------------------

A checklist was applied to assess the quality of the studies selected after the abstract and content review. This checklist included 14 questions using the National Institutes of Health (National Heart, Lung and Blood Institute) checklist for observational, cohort and cross-sectional studies \[[@B18]\]. All the fourteen questions were applicable to our study and all the aspects of the methodology like study objectives, defined study population, the participation rate of eligible subjects, clearly defined exposure as well as outcome measures, measurement of exposure prior outcome, sufficient duration of follow-up and, the statistical adjustment of confounding variables were evaluated. Each question was graded as Yes, No, and Others---CD, can not determine/NA, not applicable/NR, not reported. The studies with 11--14 'Yes' responses, were considered good and studies with 7--10 'Yes' responses were considered fair. Studies with 6 or less than 6 'Yes' responses were considered to be of poor quality.

6. Statistical analysis {#sec6}
-----------------------

Meta-analysis was performed in STATA version 13.0 (College Station, TX, USA). The forest plot was constructed using midas package in STATA. The midas package uses "mixed-effects logistic regression framework" to provide the pooled estimate of sensitivity and specificity. Anticipating substantial methodological as well as statistical heterogeneity we adopted a random effects model for meta-analysis. An attempt was made to reduce the heterogeneity by considering cohort studies which carried out high-risk HPV DNA testing and followed up the cases for a minimum period of 1 year. The sensitivity and specificity estimates of individual studies with 95% CI, pooled sensitivity and specificity with 95% CI, chi-square statistic for heterogeneity and I^^2^^ Statistic are depicted in forest plot ([Fig. 2](#F2){ref-type="fig"}).

![Forest plots of pooled sensitivity and specificity of human papillomavirus DNA testing after radiation of cervical cancer cases.\
CI, confidence interval.](jgo-31-e20-g002){#F2}

7. Assessment of publication bias {#sec7}
---------------------------------

For assessment of publication bias Egger\'s test was used \[[@B19]\]. The Egger\'s test includes a weighted linear regression with standardized effect estimate as the dependent variable and precision as the independent variable. In the present study log~e~ diagnostic OR was considered as the effect estimate and the precision was given as 1/standard error of log~e~ diagnostic OR. Weights were assigned by the inverse variance approach (1/variance of the effect estimate). A statistically significant slope coefficient provides evidence for presence of publication bias.

RESULTS
=======

Through electronic database search, 758 articles were identified and screened for eligibility and 388 titles were excluded. Abstracts of 370 titles were reviewed and 29 abstracts were found to be eligible for the full-text review. Full-text articles were retrieved for 29 studies. For the final meta-analysis, ten studies were qualified.

Most of the available data were from Japan, India, Austria, Italy, Korea, and Sweden. The number of enrolled cancer cases varied between 18 and 204. Only pre-radiation HPV DNA status was checked in 2 studies included for meta-analysis \[[@B20][@B21]\]. Five studies subjected the patients to molecular tests pre- as well as post-radiotherapy \[[@B9][@B22][@B23][@B24][@B25]\]. Study participants treated by concurrent chemoradiotherapy were also included for molecular testing in 3 studies considered for meta-analysis \[[@B8][@B24][@B26]\]. High-risk HPV persistence post-radiotherapy was reported to be associated with recurrence in most of the studies. The HPV detection rate after radiation and/or chemoradiation ranged between 18.6% and 93% \[[@B8][@B9][@B27]\]. As shown in the [Table 1](#T1){ref-type="table"}, studies screened patients starting from third month of pelvic irradiation reported higher persistence of HPV infection. Even though the study which reported the highest rate of detection screened the cases immediately after radiation, did not specify the exact time interval \[[@B28]\]. Since 8--12 weeks duration is essential to experience the maximum therapeutic effect of radiation, most of the studies performed HPV DNA testing starting from 12 weeks after completion of radiotherapy. The occurrence of high-risk HPV DNA was observed to be a significant predictor of local relapse and overall survival rate.

###### Cohort studies regarding HPV DNA detection in cervical cancer cases after radiotherapy

![](jgo-31-e20-i001)

  Reference                        Year   Region           No. of cases   Concurrent chemotherapy received   HPV DNA positive (pre-RT)   HPV DNA positive (post-RT)   Time of HPV testing after treatment   HPV types detected                               Follow-up (mo)         Recurrences (HPV+ and HPV−ve cases)   Quality assessment
  -------------------------------- ------ ---------------- -------------- ---------------------------------- --------------------------- ---------------------------- ------------------------------------- ------------------------------------------------ ---------------------- ------------------------------------- --------------------
  Bachtiary et al. \[[@B30]\]      2002   Austria          106            No                                 \-                          42 cases (43.7)              Every 3 months                        16, 18, 31, 33, 45, 69, 73                       Mean 50 (45.8--54.2)   27 in HPV+ve                          Good
  18 in HPV−ve                                                                                                                                                                                                                                                                                                            
  Harima et al. \[[@B20]\]         2002   Japan            84             No                                 64 (50)                     \-                           Not done                              16, 18, 31, 33, 58, 52                           Mean 31.3 (1--78.5)    37 in HPV+                            Good
  5 in HPV−ve                                                                                                                                                                                                                                                                                                             
  Nagai et al. \[[@B22]\]          2004   Japan            97             No                                 97                          55 (56.7)                    Every 3 months                        16, 18, 45, 56                                   Mean 52.4 (6--102)     19 in HPV+                            Good
  3 in HPV−ve                                                                                                                                                                                                                                                                                                             
  Singh et al. \[[@B28]\]          2006   Kolkata, India   56             No                                 \-                          44 (78.5)                    Once soon after treatment             HPV-16, 18 other high-risk HPV                   60                     14 in HPV+                            Good
  0 in HPV−ve                                                                                                                                                                                                                                                                                                             
  Badaracco et al. \[[@B24]\]      2010   Italy            18             3/18 received                      16                          10 (62.5)                    Once soon after treatment             16, 18, 58, 45, 31                               18                     3 in HPV+                             Good
  2 in HPV−ve                                                                                                                                                                                                                                                                                                             
  Song et al. \[[@B9]\]            2010   Korea            156            No                                 123                         29 (18.6)                    1, 3, 6, 12 months                    High-risk HPV not typed                          24                     14 in HPV+                            Good
  4 in HPV−ve                                                                                                                                                                                                                                                                                                             
  Intharaburan et al. \[[@B26]\]   2012   Thailand         55             Yes                                \-                          25 (45.5)                    2 months                              16, 18, 52, 58                                   Mean 13 (3--22)        6 in HPV+                             Good
  1 in HPV−ve                                                                                                                                                                                                                                                                                                             
  Mahantshetty et al. \[[@B8]\]    2017   Mumbai, India    135            129/135 received                   126                         89 (70.6)                    Every 3 months till 24 months         16, 18                                           24                     44 in HPV+                            Good
  29 in HPV−ve                                                                                                                                                                                                                                                                                                            
  Okonogi et al. \[[@B21]\]        2017   Japan            83             No                                 69 (83.1)                   \-                           \-                                    16, 18, 31, 33, 35, 39, 45, 52, 56, 58, 59, 68   72                     37 in HPV+                            Good
  6 in HPV−ve                                                                                                                                                                                                                                                                                                             
  Kaliff et al. \[[@B27]\]         2018   Sweden           204            No                                 \-                          189 (93)                     Not available                         16, 18, 31, 33, 35, 39, 45, 56                   60                     83 in HPV+                            Good
  0 in HPV−ve                                                                                                                                                                                                                                                                                                             

Values are presented as number (%).

HPV, human papillomavirus; RT, radiotherapy; ve, negative.

1. Viral factors augmenting the recurrence rate {#sec1___1}
-----------------------------------------------

Studies have reported that cases associated with HPV DNA clearance after radiation demonstrate better prognosis and viral persistence may imply apparent treatment failure \[[@B24][@B29]\]. In comparison to a single genotype, infection with multiple genotypes was associated with poor prognosis and early recurrences \[[@B30]\]. The study from Chennai reported that the occurrence of HPV58, HPV18 and multiple infections were associated with increased probability of recurrence following radiotherapy \[[@B31]\]. Cervical cancers with infections by many HPV genotypes including at least 1 high-risk genotype were observed to be having 5 times greater risk of radiotherapy failure when compared to cancer cases positive for a single high-risk HPV DNA \[[@B31]\].

The persistence of HPV18 after radiotherapy would result in a 4-fold increased risk of recurrence \[[@B32]\]. HPV 18 was observed to be more resistant to surgery as well as to chemoradiation, suggesting more aggressive nature of this genotype \[[@B33]\]. The occurrence of high-risk HPV DNA at 24 months post-radiotherapy implies a greater risk of local recurrence \[[@B9]\]. A recent study from Sweden observed that detection of certain high-risk genotypes including HPV16 and 18 during follow-up was associated with greater frequency of distant metastases \[[@B27]\]. There is vast variation in HPV DNA detection tests employed in studies and the detection rates varied between 18.6% and 93.0% \[[@B9][@B33][@B34]\]. In comparison with cervical cancer cases associated with HPV-16, the relative risk of death in patients with HPV negative cancers was 1.64 \[[@B34]\]. The systematic review and meta-analysis by Li et al reported that the pre-treatment HPV DNA status is a clinically useful prognostic biomarker in cervical cancer cases \[[@B35]\]. There exists a higher risk of local recurrence if HPV DNA persists after radiation \[[@B22]\]. HPV detection after radiation is a significant tool to assess the effectiveness of treatment \[[@B24]\].

A low HPV load prior radiotherapy or surgery was observed to be having poor prognosis and short disease free survival as a result of aggressive nature of the malignancy \[[@B36]\]. Post-radiation, high viral load observed in late-stage cervical cancers was associated with higher recurrence rate in certain studies \[[@B9][@B24][@B25][@B28]\]. Poorly differentiated tumours were observed to be having low viral load in contrast to well or moderately differentiated tumours. The overall pooled sensitivity of HPV DNA testing was 0.84 (95% CI=0.66--0.94). The overall pooled specificity of HPV DNA testing was 0.35 (95% CI=0.20--0.54). The positive likelihood ratio was 1.3 (95% CI=1.0--1.7) implying that a positive result is more likely to occur in people with relapse than people without the relapse. The negative likelihood ratio was 0.45 (95% CI=0.18--1.10). The estimated OR was 3 (95% CI=1--9) denoting that a cervical cancer case with positive HPV DNA test after radiation has 3 times the odds of developing the recurrence in comparison to cervical cancer tested negative for HPV DNA after radiation. The p-value for the slope coefficient is 0.12, which is statistically non-significant ([Table 2](#T2){ref-type="table"}). There is no evidence for presence of publication bias.

###### The table depicting the results of Egger\'s test

![](jgo-31-e20-i002)

  Coefficient   Estimate (95% CI)     p-value
  ------------- --------------------- ---------
  Intercept     3.67 (−0.33, 7.68)    0.07
  Slope         −1.90 (−4.39, 0.58)   0.12

CI, confidence interval.

DISCUSSION
==========

The meta-analysis presented here included ten prospective cohort studies published in the last two decades, assessing the role of HPV DNA testing to detect early relapse among 1,055 cervical cancer cases who had received radiation. Studies from Austria, Japan, India, Italy, Korea, Sweden, and Thailand were qualified for the meta-analysis \[[@B8][@B9][@B20][@B21][@B22][@B24][@B26][@B27][@B28][@B30]\]. The present study observed a high pooled sensitivity of HPV DNA based screening for detection of relapses after pelvic irradiation of cervical cancer. The cervical cancer cases screened positive for HPV DNA has 3 times the odds of recurrence or relapse. Meanwhile pooled specificity was low and thus HPV testing is not confirmatory of recurrence. This is in accordance with the previous studies reporting a low specificity of high-risk HPV testing during follow-up \[[@B37]\]. The present literature review observed vast variation in the HPV detection rate which was attributed to the disparities in the duration of follow-up, staging of enrolled cancer cases, the timing of procurement of samples in relation to pelvic irradiation, age group of enrolled cases and methods of radiotherapy. Nevertheless, a positive high-risk HPV test is the most significant independent predictor of relapse \[[@B9]\]. Study participants were treated by concurrent chemoradiotherapy in only 3 studies considered for meta-analysis and there was vast disparity in the number of cases treated by concurrent chemoradiation. As the low number of studies limit the power of regression to detect significant effects, meta-regression was not carried out.

Singh et al. \[[@B28]\] observed that the detection of high HPV DNA titres in plasma and tissue samples is a very sensitive biomarker of recurrence. HPV is an epitheliotropic virus requiring differentiating squamous epithelium for the life cycle. A recent study, reported HPV positivity in serum samples of patients with HPV-associated cervical, and oropharyngeal cancers \[[@B38]\]. A statistically significant association with viral load and prognosis was not reported. Meanwhile, HPV DNA positivity is the single most important predictor of recurrence at any time during follow-up \[[@B37]\].

Better response to radiotherapy and overall survival rate were observed in HPV positive cancers of head and neck \[[@B39]\], vagina \[[@B40]\], and cervix \[[@B37]\] when compared to cancers with HPV negativity. Elevated levels of mutated p53 may be attributed to the low survival rate of HPV negative cancer patients. The apoptosis of damaged DNA as a result of radiation therapy depends on tumour suppressor gene p53. Despite viral E6 protein-mediated degradation of p53, a fraction of p53 is still functional in HPV positive tumours conferring improved response to radiotherapy unlike HPV negative cancers \[[@B27]\]. Infection with multiple genotypes of HPV would result in a further decline in p53 owing to increased viral oncoprotein levels.

Research on targeted treatment at HPV viral molecular pathways such as proteasome inhibitors and histone deacetylase inhibitors as well as customized viral immunotherapy is in progress leading to more effective control of this cancer.

In the final analysis, cohort studies with minimum 1-year follow-up published in high quality, indexed journals were included. To the best of our knowledge, this is the first meta-analysis reporting the pooled sensitivity, pooled specificity, positive likelihood ratio, negative likelihood ratio and an OR of HPV based screening of cervical cancers treated by radiotherapy. Most of the previous reports focused on HPV DNA status prior to treatment. The present review will be helpful for Oncologists in modifying the current follow-up approaches.

The present systematic review and meta-analysis included published studies in English language and we could not review relevant articles published in other languages. Due to a limited number of follow-up studies, we had to include studies with even small sample size. Another limitation is that the present review did not consider various modes of radiotherapy received.

Annual HPV DNA testing during the initial 2 years of follow-up may facilitate early recognition of recurrence in cervical cancer survivors. Large cohort studies involving cervical cancer cases tested HPV positive before and after radiation are essential for deciding the optimal timing of molecular tests.

Further research is mandatory to understand the mechanism behind the variation in radio-sensitivity of different HPV genera. Hospital-based cohort studies enrolling HPV associated cervical cancer cases receiving radiotherapy from African, Eastern European, and Latin American countries having the highest disease burden are essential. Pretreatment HPV genotyping facilitating personalized treatment may improve recurrence-free survival rate. If further studies identify that persistent HPV virus is a strong predictor or recurrence in the post-irradiated setting, a simple hysterectomy may have a role in preventing central recurrence in a small subset of patients. De-intensification of radiation treatment in selected HPV-positive oropharyngeal squamous cell cancers, as well as cervical cancers, have to be considered after large clinical trials. Long-term follow-up studies using various clinical samples for better understanding of the natural history of HPV and blood stream spread resulting in distant metastases are essential.
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